Health Canada has formally published its approval notice for the generic semaglutide injection developed by OneSource Pharma in partnership with Dr. Reddy's Laboratories, regulatory records confirmed Thursday, a milestone that opens Canada's fast-growing GLP-1 drug market to lower-cost competition for the first time. The approval follows the initial announcement of the Health Canada nod on April 29 and advances the two companies' stated ambition to expand patient access across North America.
Dr. Reddy's Laboratories, the Hyderabad-headquartered pharmaceutical giant, will serve as the commercial anchor for Canadian distribution, leveraging its existing regulatory relationships and supply infrastructure in the country. OneSource Pharma, acting as the contract development and manufacturing organisation, will produce the active pharmaceutical ingredient and finished dosage form at its certified facilities. Analysts at Jefferies noted Thursday that the approval is likely to place immediate pricing pressure on Novo Nordisk's Ozempic and Wegovy franchises in Canada, where list prices have remained elevated relative to peer markets.
The timing is commercially significant. Novo Nordisk has faced persistent supply constraints for semaglutide products in Canada over the past eighteen months, creating an opening for generic entrants to capture patients who have been unable to access branded formulations. Canadian provincial drug plans, several of which have been evaluating reimbursement pathways for GLP-1 therapies in obesity management, are expected to review the Dr. Reddy's submission in coming weeks with an eye toward cost-effectiveness benchmarks.
Dr. Reddy's shares rose modestly on the Bombay Stock Exchange in Thursday trading as investors welcomed the Health Canada clearance as validation of the company's CDMO partnership strategy. The approval also signals growing regulatory confidence in biosimilar and generic GLP-1 manufacturing standards, which had been a sticking point for several rival applications that were returned to sponsors for additional clinical bridging data in 2025.
Industry observers expect the Canadian clearance to serve as a reference point as OneSource and Dr. Reddy's pursue equivalent applications with the U.S. Food and Drug Administration and the European Medicines Agency. The companies have not yet disclosed a Canadian launch date or pricing, but healthcare system negotiations with provincial payers are understood to be at an advanced stage, with British Columbia and Ontario identified as the most likely first markets for formulary listing.